123 related articles for article (PubMed ID: 32234272)
1. A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
Matsumoto S; Kijima T; Matsuoka Y; Yamamoto M; Fujii Y
Eur J Cancer; 2020 May; 131():104-107. PubMed ID: 32234272
[No Abstract] [Full Text] [Related]
2. Neoadjuvant pembrolizumab in bladder cancer.
Gourd E
Lancet Oncol; 2018 Dec; 19(12):e669. PubMed ID: 30509883
[No Abstract] [Full Text] [Related]
3. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
[TBL] [Abstract][Full Text] [Related]
4. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
[No Abstract] [Full Text] [Related]
5. Pembrolizumab associated hemophagocytic lymphohistiocytosis.
Shah D; Shrestha R; Ramlal R; Hatton J; Saeed H
Ann Oncol; 2017 Jun; 28(6):1403. PubMed ID: 28368439
[No Abstract] [Full Text] [Related]
6. Three more immune checkpoint inhibitors for advanced bladder cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
[No Abstract] [Full Text] [Related]
7. Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
Takama H; Shibata T; Ando Y; Yanagishita T; Ohshima Y; Akiyama M; Watanabe D
Eur J Dermatol; 2020 Apr; 30(2):188-190. PubMed ID: 32538362
[No Abstract] [Full Text] [Related]
8. Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
Kobayashi Y; Iijima K; Kondo Y; Yamamoto K; Sekijima Y
Acta Neurol Belg; 2024 Jun; 124(3):1063-1065. PubMed ID: 38010574
[No Abstract] [Full Text] [Related]
9. Pembrolizumab-induced hepatitis: diagnosis and treatment.
Forschner A; Schraml C; Pierchalla K; Weide B; Eigentler TK; Lauer UM; Garbe C
J Dtsch Dermatol Ges; 2017 Sep; 15(9):933-935. PubMed ID: 28872228
[No Abstract] [Full Text] [Related]
10. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer.
Rentsch CA; Hayoz S; Cathomas R
Lancet Oncol; 2021 Sep; 22(9):e379. PubMed ID: 34478663
[No Abstract] [Full Text] [Related]
12. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
[No Abstract] [Full Text] [Related]
13. Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply.
Balar AV; Kamat AM; de Wit R;
Lancet Oncol; 2021 Sep; 22(9):e380. PubMed ID: 34478664
[No Abstract] [Full Text] [Related]
14. Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
Pelster MS; Mott F; Lewin J
Laryngoscope; 2020 Apr; 130(4):E140-E143. PubMed ID: 31074845
[TBL] [Abstract][Full Text] [Related]
15. [The role of immunooncology in the treatment of urothelial cancer].
Retz M; Tauber R; Horn T
Aktuelle Urol; 2017 Aug; 48(4):329-335. PubMed ID: 28591872
[TBL] [Abstract][Full Text] [Related]
16. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
17. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
[No Abstract] [Full Text] [Related]
18. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
Eur J Cancer; 2019 Mar; 110():49-52. PubMed ID: 30739840
[No Abstract] [Full Text] [Related]
19. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Nardin C; Pelletier F; Puzenat E; Aubin F
Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
